Shi Jinan, Duan Yin, Pan Lei, Zhou Xiaoxi
Department of Medical Oncology, Zhejiang Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
Department of Breast Surgery, Zhejiang Provincial Traditional Chinese Medical Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
Onco Targets Ther. 2016 Jun 13;9:3493-500. doi: 10.2147/OTT.S104734. eCollection 2016.
Cluster of differentiation 44 (CD44) is an important surface marker of cancer stem cells in a variety of tumors. A number of previous studies have been conducted to investigate the association between CD44 gene rs13347 C>T polymorphism and cancer risk in humans; nevertheless, the results remain controversial. We therefore performed this meta-analysis to confirm the role of this polymorphism in susceptibility to human cancer.
The studies published up to December 2015 were searched in PubMed, Web of Science, and China National Knowledge Infrastructure databases. Twelve eligible case-control studies were identified, involving a total of 6,982 cases and 7,430 controls. Pooled odds ratio (OR) and corresponding 95% confidence interval (CI) were calculated using a fixed or random-effect model to estimate the strength of the association.
The results of the overall analyses indicated that CD44 gene rs13347 polymorphism was significantly associated with cancer risk in Asians (CT vs CC: OR =1.35, 95% CI =1.12-1.62; TT vs CC: OR =1.99, 95% CI =1.52-2.60; TT + CT vs CC: OR =1.41, 95% CI =1.16-1.71; and TT vs CC + CT: OR =1.74, 95% CI =1.41-2.14), especially in Chinese population (CT vs CC: OR =1.42, 95% CI =1.16-1.75; TT vs CC: OR =2.13, 95% CI =1.58-2.86; TT + CT vs CC: OR =1.50, 95% CI =1.21-1.87; and TT vs CC + CT: OR =1.80, 95% CI =1.43-2.26). In stratified analyses by cancer types, there was evidence for an association between this polymorphism and nasopharyngeal cancer and breast cancer, respectively.
The results of this meta-analysis suggest that the CD44 gene rs13347 C>T polymorphism is associated with elevated risk of human cancer in Asians, especially in Chinese population. Further well-designed studies on a larger population covering other ethnicities should be carried out to validate our results.
分化簇44(CD44)是多种肿瘤中癌症干细胞的重要表面标志物。此前已有多项研究探讨CD44基因rs13347 C>T多态性与人类癌症风险之间的关联;然而,结果仍存在争议。因此,我们进行了这项荟萃分析,以证实该多态性在人类癌症易感性中的作用。
检索了截至2015年12月在PubMed、科学网和中国知网数据库中发表的研究。确定了12项符合条件的病例对照研究,共涉及6982例病例和7430例对照。使用固定效应或随机效应模型计算合并比值比(OR)及相应的95%置信区间(CI),以估计关联强度。
总体分析结果表明,CD44基因rs13347多态性与亚洲人的癌症风险显著相关(CT vs CC:OR =1.35,95% CI =1.12 - 1.62;TT vs CC:OR =1.99,95% CI =I.52 - 2.60;TT + CT vs CC:OR =1.41,95% CI =1.16 - 1.71;TT vs CC + CT:OR =1.74,95% CI =1.41 - 2.14),尤其是在中国人群中(CT vs CC:OR =1.42,95% CI =1.16 - 1.75;TT vs CC:OR =2.13,95% CI =1.58 - I.86;TT + CT vs CC:OR =1.50,95% CI =1.21 - 1.87;TT vs CC + CT:OR =1.80,95% CI =1.43 - 2.26)。在按癌症类型进行的分层分析中,分别有证据表明该多态性与鼻咽癌和乳腺癌之间存在关联。
这项荟萃分析的结果表明,CD44基因rs13347 C>T多态性与亚洲人尤其是中国人群患人类癌症的风险升高有关。应开展进一步针对涵盖其他种族的更大人群的精心设计研究,以验证我们的结果。